Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery

INTRODUCTION: Although third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected stage IIIA non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, the optimal treatment sequencing of EGFR-TKIs, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Wenyan, Sheng, Ziyi, Niu, Yongliang, Yan, Bo, Chen, Yong, Yang, Haitang, Li, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618502/
https://www.ncbi.nlm.nih.gov/pubmed/37920491
http://dx.doi.org/10.1016/j.heliyon.2023.e20955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618502/
https://www.ncbi.nlm.nih.gov/pubmed/37920491
http://dx.doi.org/10.1016/j.heliyon.2023.e20955

Ejemplares similares